Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
| العنوان: | Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial |
|---|---|
| المؤلفون: | Frank Vercruysse, Guillaume Charpentier, John P.H. Wilding, Gordon Law, Priscilla Hollander, Gary Meininger, Guillermo Gonzalez-Galvez, William Canovatchel, S. Black, Chantal Mathieu, Keith Usiskin |
| المصدر: | International Journal of Clinical Practice |
| بيانات النشر: | BlackWell Publishing Ltd, 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Blood Glucose, Male, endocrine system diseases, Blood Pressure, law.invention, Endocrinology, Randomized controlled trial, Glucosides, law, Weight loss, Insulin-Secreting Cells, Canagliflozin, Aged, 80 and over, General Medicine, Middle Aged, Metformin, Treatment Outcome, Female, medicine.symptom, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Thiophenes, Placebo, Drug Administration Schedule, Young Adult, Double-Blind Method, Diabetes mellitus, Internal medicine, Weight Loss, medicine, Humans, Hypoglycemic Agents, Adverse effect, Aged, Hemoglobin A, Glycosylated, Glycated Hemoglobin, Dose-Response Relationship, Drug, business.industry, Type 2 Diabetes Mellitus, nutritional and metabolic diseases, medicine.disease, Lipid Metabolism, Sulfonylurea Compounds, Diabetes Mellitus, Type 2, business |
| الوصف: | SummaryAims Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind, placebo-controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add-on to metformin plus sulphonylurea in patients with T2DM. Methods Patients (N = 469) received canagliflozin 100 or 300 mg or placebo once daily during a 26-week core period and a 26-week extension. Prespecified primary end-point was change in HbA1c at 26 weeks. Secondary end-points included change in HbA1c at week 52 as well as proportion of patients achieving HbA1c |
| وصف الملف: | Print-Electronic |
| اللغة: | English |
| تدمد: | 1742-1241 1368-5031 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a821c022ef94271cbd9478662ad4ecd8Test http://europepmc.org/articles/PMC4282288Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....a821c022ef94271cbd9478662ad4ecd8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17421241 13685031 |
|---|